Figure 3.
Year-over-year change in the yearly dispensed amount of various drug groups used for type 2 diabetes. The panels from top left represent total T2D drugs (ATC group A10B, plus insulins to patients with T2D), SGLT2 inhibitors (sodium-glucose cotransporter-2 inhibitors), GLP-1 analogues (glucagon-like peptide-1 receptor agonists), DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), insulins (ATC group A10A, only to patients also prescribed any drug from ATC group A10B) and sulfonylureas. For all graphs, red colour indicates the intervention group and blue colour indicates the control group. The shaded areas represent 95% confidence intervals of the day-to-day estimates. On the y-axis, a plus sign denotes an increase whereas a minus sign denotes a decrease.